Recently, the therapeutical use of second-generation androgen-receptor-axis-targeted agents (ARAT) like apalutamide and enzalutamide has gained growing attention, especially in the treatment of metastatic, castration-sensitive PC. This evidence concerns the gene AR and pachyonychia congenita.